Incyte Corp
NASDAQ:INCY

Watchlist Manager
Incyte Corp Logo
Incyte Corp
NASDAQ:INCY
Watchlist
Price: 68.535 USD -0.41%
Market Cap: 13.2B USD
Have any thoughts about
Incyte Corp?
Write Note

Incyte Corp
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Incyte Corp
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Incyte Corp
NASDAQ:INCY
Revenue
$4.1B
CAGR 3-Years
12%
CAGR 5-Years
14%
CAGR 10-Years
24%
Abbvie Inc
NYSE:ABBV
Revenue
$55.5B
CAGR 3-Years
0%
CAGR 5-Years
11%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Revenue
$28.3B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Revenue
$32.5B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
5%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Revenue
$10.6B
CAGR 3-Years
14%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Revenue
$13.8B
CAGR 3-Years
1%
CAGR 5-Years
16%
CAGR 10-Years
18%
No Stocks Found

Incyte Corp
Revenue Breakdown

Breakdown by Geography
Incyte Corp

Total Revenue: 3.7B USD
100%
United States: 3.5B USD
94.7%
Europe And Japan: 179.3m USD
4.9%

Breakdown by Segments
Incyte Corp

Total Revenue: 3.7B USD
100%
Product Revenues, Net: 3.2B USD
85.6%
Product Royalty Revenues: 523.5m USD
14.2%
Jakavi: 367.6m USD
9.9%
Opzelura: 337.9m USD
9.1%
Olumiant: 136.1m USD
3.7%
Jakafi: 122.1m USD
3.3%
Tabrecta: 17.8m USD
0.5%
Milestone And Contract Revenues: 7m USD
0.2%
Show More
Show Less

Incyte Corp
Glance View

Market Cap
13.2B USD
Industry
Biotechnology
Economic Moat
None

Incyte Corporation stands as a significant player in the biopharmaceutical landscape, where its roots are firmly planted in the research and development of novel therapeutics. Founded in 1991, Incyte initially carved its path focusing on genomics before pivoting towards drug development. This transformation catalyzed its growth, anchored by its commitment to discovering innovative ways to tackle unmet medical needs in oncology and inflammation. The company’s forte lies in its robust pipeline of targeted therapies, leveraging small molecules and monoclonal antibodies to alter the course of diseases. Incyte's approach is driven by a deep understanding of the biological pathways that underpin human health, allowing it to develop medicines that offer new hope to patients suffering from debilitating conditions. Incyte's commercial success is largely attributed to its flagship product, Jakafi (ruxolitinib), a groundbreaking oral selective inhibitor of Janus Associated Kinases (JAK1 and JAK2). Approved for the treatment of specific types of myelofibrosis and polycythemia vera, Jakafi represents a crucial revenue stream for the corporation. Beyond Jakafi, Incyte has been fruitful in diversifying its portfolio, fostering collaborative partnerships, and strategically licensing its assets to expand market reach and share risks. This dual strategy of internal innovation and external collaboration not only fuels Incyte’s financial engine but also reinforces its position in a competitive marketplace, as it continuously seeks out new frontiers in medical science to address complex diseases worldwide.

INCY Intrinsic Value
88.271 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Incyte Corp's Revenue?
Revenue
4.1B USD

Based on the financial report for Sep 30, 2024, Incyte Corp's Revenue amounts to 4.1B USD.

What is Incyte Corp's Revenue growth rate?
Revenue CAGR 10Y
24%

Over the last year, the Revenue growth was 13%. The average annual Revenue growth rates for Incyte Corp have been 12% over the past three years , 14% over the past five years , and 24% over the past ten years .

Back to Top